Oral Small-Molecule GLP-1 Agonists
Non-peptide molecules that activate the GLP-1 receptor after oral dosing, removing the injection, cold-chain and peptide-manufacturing constraints that limit incretin obesity therapy.
Developed mainly in: United States and ChinaImpacting: North America, Europe, China and Rest of Asia
Ascletis Pharma received FDA clearance and initiated a global Phase III program for ASC30, an oral small molecule GLP-1 drug targeting obesity, enrolling ~4,600 participants across the US, Europe, and Canada. The company also reported positive preclinical primate data for a first-in-class oral GLP-1/GIP/amylin triple fixed-dose combination pill.
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
25 March 2026 · score 9.0/10
Corroborating sources since flagging
62
Latest signals
Tracked from 6 signals, each traced to its source.
- Oral small-molecule GLP-1 orforglipron clears FDA under 50-day priority voucher review
Rhizomeai · 5 Oct 2026
- Chinese biotech begins global Phase III trials of oral GLP-1 obesity pill
Prnewswire · 24 Sept 2026
- Ascletis Launches Global Phase III Trial for Once-Daily Oral GLP-1 Obesity Pill
Prnewswire · 7 Aug 2026
3 more signals with dates, scores and flags in the full record. See them all →
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Healthcare
Other innovations the engine is currently tracking in this industry.
- Image-Based Cancer Prognostic Modelling6.5/ 10 · 2 signals
- Hospital-At-Home Continuous Vital-Sign Patches5.0/ 10 · 2 signals
- Automated Quantitative Imaging Biomarkers5.5/ 10 · 2 signals
- Prescription Digital Therapeutics7.0/ 10 · 10 signals
- At-Home Prescription Neuromodulation6.5/ 10 · 2 signals
- Clinical-Grade Wearable Biosensing6.0/ 10 · 2 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.